Appendix 1: Qualitative Semi-structured Questionnaire at Baseline

Respondent demographics

Name	Role	Centre
PG degree		

Attitudes about HCV treatment

- 1. Do you think treating HCV would be of benefit to some or all of your clients?
- 2. Why/why not would HCV treatment be of benefit?
- 3. What would you perceive as barriers to treatment in the current model (hospital-based treatment of HCV)?

Primary care site

Secondary/Tertiary care site

Health care system

Clients

4. Where do you think would be the best (location/provider) of treating HCV?

Attitudes to ECHO

- 5. Have you heard of ECHO? Yes No Maybe
- 6. If yes: How/when did you hear about ECHO

Explain (video link-up with specialists to support PCPs in providing treatment):

- 7. What do you think of ECHO?
- 8. Would you be interested in taking part in the ECHO pilot?
- 9. What would you hope that ECHO would provide?

- 10. What would you need to take part in the ECHO pilot?
- 11. What would you perceive as barriers to an ECHO-based model of care

PCP site Secondary/Tertiary care site Health care system Clients

12. How could we overcome the barriers?

Your practice: Complete site assessment document with participant

- 13. Number of clients you would foresee being suitable for HCV treatment via ECHO?
- 14. Length of time you foresee needing ECHO?
- 15. What other diseases would be amenable to management via ECHO?
- 16. Any other thoughts on needs of your clients?

Appendix 2: Qualitative Semi-structured Questionnaire (Completion of Intervention)

Administered by:

Respondent demographics

Name	Role	Centre
PG degree		

Impact of participation in ICORN ECHO pilot

1.	Did participation	n in the ICORN ECHO $ $	pilot improve v	vour competenc	v in mana	aging HCV?
	Dia participation	1 111 1110 10 01 111 1 201 10	phot improve	your compoterio	y iii iiiaiic	agii ig i i o v .

Yes No Maybe How?

2. Did your participation in the ICORN ECHO pilot benefit your clients?

Yes No Maybe How?

3. Did your participation in the ICORN ECHO pilot benefit you?

Yes No Maybe How?

4. Did your participation in the ICORN ECHO pilot benefit your colleagues?

Yes No Maybe How?

Views on ICORN ECHO pilot

- 5. Were there any particular aspects of the ICORN ECHO pilot you found beneficial?
- 6. Were there any aspects of the ICORN ECHO pilot you found less helpful?
- 7. Did you feel the amount of time allocated to each patient was sufficient?
- 8. Did you find the HCV teaching helpful?
- 9. What would you perceive as barriers to an ECHO-based model of care

PCP site

Secondary/Tertiary care site

Health care system

Clients

10. How could we overcome the barriers?

11. How did you find preparing the patients for discussion?

- 12. How did you find the case discussions?
- 13. How did you find the follow-up suggestions?
- 14. Any other suggestions for improving ICORN ECHO?
- 15. What other diseases would be amenable to management via ECHO?
- 16. Any other thoughts on needs of your clients?

Views on study assessments

- 17. How did you find the case vignettes?
- 18. How did you find the self-efficacy questionnaires?
- 19. How did you find the interview at the start of the ICORN ECHO pilot?
- 20. How did you find this interview?

Appendix 3: Recruitment Record

Site approached regarding participation in ICORN ECHO:				
Date(s) approached:				
How was site identified:				
Type of site: GP Practice: Drug Treatment Centre:				
Hostel: Other (describe):				
Individual(s) approached re participation (name, position):				
Individual(s) from ICORN ECHO involved in discussion with participants:				
Drivers regarding taking part in ICORN ECHO:				
Barriers to taking part in ICORN ECHO:				
Willing to take part: Y N				
Qualitative semi-structured interview carried out: V N				

Appendix 4: Case Conference Script

- > Welcome to all participants
- > Introduce all participants/roll call
- > Reminder re etiquette
 - Muting during presentation
 - Raise hand if wish to speak
 - Confidentiality
 - Participation does not establish patient-provider relationship
 - Recording
 - o 2 cases/site, maximum 10 mins per case

> Programme

- Teaching
- Case presentation/discussion:
 - Waterford
 - Sundial
 - Trinity Court
- Questions
- o Reminder re feedback forms
- Reminder re date of next conference

Appendix 5: Case Conference Record To be completed by ICORN progamme manager

Date:
Time:
Sites present:
Participants present:
Presenters:
Teaching topic:
Duration of teaching:
Number of questions asked by participants related to teaching:
Number of cases discussed:
Number of non-case based questions discussed:
Any technical issues: Y N If yes, please describe:
Any other issues (please describe):

ICORN ECHO HCV PILOT Appendix 6: Case Discussion Record

ECHO ID:	
Site:	
Presenter:	
Questions:	
Advised by:	
Advice given:	
Outcome of discussion:	
Action points: Yes□	No□
Scheduled for discussion ag	gain? Yes□ No□

ICORN ECHO HCV PILOT

Appendix 7: Case Registration Form

ECHO ID:	
SITE:	
CLINICIAN:	
Screening Encounter Date:	
D	
EMOGRAPHICS	SUSPECTED ROUTE OF HCV
Gender: $M \square F \square$	TRANSMISSION (check all that apply):
Marital Status: Co-habiting □ Divorced □	Current or former injection drug user (even once)□
Married □ Separated □ Single □ Unknown □	Recipient of blood products□
Widowed □	Healthcare associated□
Ethnicity: Irish □ Western European □	Vertical acquisition□
Eastern European ☐ Traveller ☐ Asian ☐ African	Sexual transmission□
□ Other □	Sharing razors/tooth brushes with a HCV infected
Country of Origin:	person□
Number of years completed in school:	Non-professional tattoo□
Stable Housing: $Y \square$ $N \square$	Intranasal drug use□
Ever incarcerated: $Y \square$ $N \square$	Unknown□
Medical Card: $Y \square$ $N \square$	
Primary care provider (GP):	
MEDICAL DIAGNOSES:	Arthritis□
HIV□	
Coronary Artery Disease□	
Diabetes Mellitus□	
Hypertension□	
Cerebrovascular Disease□	
Peripheral Vascular Disease□	
Dyslipidaemia□	
Hyperthyroidism□	
Hypothyroidism□	
Autoimmune Disease□	
Cancer□	
Kidney disease (stage if yes):□	
Asthma□	
$COPD\Box$	
Chronic Pain□	
Peripheral Neuropathy□	
Seizure Disorder□	

Brain Injury \square Transplant \square

LIVER-RELATED HISTORY:	No. of attempts Date of last
Year of HCV diagnosis:	attempt:
Hepatitis B:□	Hospitalization for psychiatric reasons
Cirrhosis:□	
Ascites:□	If yes, date of last hospitalisation:
Date: Result:	Undergoing psychotherapy/counselling
Hep C PCR result: Date:	
Hep C genotype:	SUBSTANCE USE HISTORY:
Esophageal varices:□	Alcohol: One standard drink = 1 glass
Upper GI bleed:□	beer, 1 small glass wine (1 bottle = 7
	units), 1 measure of spirits
Handis Encaphalandas -	Does the patient currently drink alcohol:
Hepatic Encephalopathy□	Yes □ No□
Previous HCV treatment? Yes □ No□	If Yes: Average number of units/week:
If yes:	Drugs:
Date: Drug regime:	Does the patient use drugs other than
	alcohol currently? Yes □ No□
Tx duration: Tx response:	If yes, number of uses/week of:
Liver biopsy: Yes □ No□	Heroin:
If yes:	Benzodazepines:
	Head-shop products:
	Marijuana:
	Stimulants:
VACCINATIONS:	Cigarettes: Yes □ No□
Hepatitis B: Immune□	If yes, packs/day:
Vaccinated□	2, yes, paens ady.
Hepatitis A: Immune□	Is the patient on methadone? Yes \square
Vaccinated□	No□
Influenza: Vaccinated within current	If yes: Prescriber:
season□	Dispensed at:
Pneumovax: Vaccinated□	
PSYCHIATRIC DIAGNOSES:	
Depression □ On medication? Yes	
□ No□	MEDICATION LIST:
Anxiety \square On medication? Yes	
□ No□	Drug allergies: Yes \square No \square
Bipolar \square	Pleade(1 1 1 2 2 2)
Schizophrenia □	Bloods (please note date of result): FBC: Hb WCC
Personality disorder □	Platelets
Suicidal behaviour/self-harm	Liver profile:
If yes:	Albumin AST ALT

Alk	Phos	GGT		CLINICAL FINDINGS:
Bilirubin				Height:
				Weight:
Creatinine	:			Encephalopathy:
INR:				None:□
Glucose:				Grade 1 - Trivial lack of awareness;
Alphafetop	orotein:			euphoria or anxiety; shortened attention
ANA:				span; impaired performance of addition or
HIV test:				subtraction, altered sleep pattern □
				Grade 2 - Lethargy or apathy;
IMAGINO	3 :			disorientation for time; obvious
Abdomina	l ultrasound:	Yes □	No	personality change; dyspraxia, asterixis
				Grade 3 - Somnolence to semistupor but
<i>If yes:</i>				responsive to stimuli; confusion; gross
Date:	Result:			disorientation, bizarre behaviours \Box
Abdomina	l CT:	Yes □	No	Grade 4: Coma □
				Ascites:
<i>If yes:</i>				None:□
Date:	Result:			Controlled with diuretics:□
Abdomina	l MRI:	Yes □	No	Not controlled with
				Not controlled with
diuretics:				

Appendix 8: Case Conference Record

General information request (if not specific to a single patient)

What is your main question?

PLEASE NOTE that ICORN ECHO case consultations do <u>not</u> create or otherwise establish a provider-patient relationship between any St James's Hospital clinician and any patient whose case is being presented in an ICORN ECHO case conference

ICORN ECHO HCV Pilot Appendix 9: Resource Utilisation Record

Date of case conference:

Preparation:

	Time Used	Cost/hour	Notes
Faculty 1 (SN)			
Faculty 2 (CB)			
Faculty 3 (AOL)			
Faculty 4 (CNC)			
Programme Manager (DB)			
Other Hub member (name)			
Participant 1 (name)			
Participant 2 (name)			
Participant 3 (name)			
Participant 4 (name)			
IT support (name)			
Other (details)			

Conference:

	Time Used	Cost/hour	Notes
Faculty 1 (SN)			
Faculty 2 (CB)			
Faculty 3 (AOL)			

Faculty 4 (CNC)		
Programme		
Manager (DB)		
Other Hub member		
(note name)		
Participant 1		
(name)		
Participant 2		
(name)		
Participant 3		
(name)		
Participant 4		
(name)		
IT support (name)		
Other (details)		

Follow-up:

	Time Used	Cost/hour	Notes
Faculty 1 (SN)			
Faculty 2 (CB)			
Faculty 3 (AOL)			
Faculty 4 (CNC)			
Programme Manager (DB)			

Other Hub member		
(note name)		
Participant 1		
(name)		
Participant 2		
(name)		
Doution ant 2		
Participant 3		
(name)		
Participant 4		
(name)		
0(1-1-(-1-1-)		
Other (details)		

Other costs: (cost, details)

ANY OTHER INFORMATION THAT YOU THINK IS IMPORTANT: